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Background. Hyperinsulinemic hypoglycemia with neuroglycopenia is a rare complication of Roux-en-Y gastric bypass (RYGB).
We hypothesized that continuous glucose monitoring (CGM) would be useful to characterize glycemic variability after RYGB.
Methods. CGM and mixed meal tolerance testing (MMTT) were performed on sixteen post-RYGB subjects, ten with a history of
neuroglycopenia on medical treatment and six asymptomatic controls. Results. 9 of 10 subjects with neuroglycopenia developed
hypoglycemia deﬁned by glucose <70mg/dL on CGM, and 3 of 9 on MMTT. In asymptomatic subjects, 3 of 6 had asymptomatic
hypoglycemia during CGM, and 3 of 5 on MMTT. Therefore, the sensitivity and speciﬁcity to detect clinically signiﬁcant
hypoglycemia was 90% and 50% for CGM and 33% and 40% for MMTT. Conclusions. Asymptomatic hypoglycemia after RYGB
is more frequent than commonly recognized. For clinicians evaluating patients for postbypass neuroglycopenia, CGM may be a
valuable diagnostic tool.
1.Introduction
Roux-en-Y gastric bypass (RYGB) results in substantial
weight loss, averaging 30–40kg (about 60% excess weight)
[1] which can be sustained over 10–15 years [2]. RYGB also
results in improvement of multiple comorbidities associated
with obesity. About 75% of patients with type 2 diabetes
w h ou n d e r g oR Y G Ba r ea b l et od i s c o n t i n u ea l ld i a b e t e s -
related medications and maintain normoglycemia [3–6].
Dyslipidemia improves or resolves in 70%–95% of surgically
treated patients and hypertension in 87%–95% [5]. In
addition, studies suggest that mortality may be decreased by
as much as 40% [2, 7].
Long-term complications of RYGB remain incom-
pletely understood. Known complications of the operation
include anemia, vitamin and mineral deﬁciencies, periph-
eral neuropathy, short term surgical complications such as
thromboembolism and small bowel obstruction, as well
as dumping syndrome, anatomic complications such as
herniation, ulceration or strictures, and multiple others [8].
Additionally, rarely patients may develop hyperinsulinemic
hypoglycemia with neuroglycopenia that typically presents
2–5 years postoperatively [9–11]. The pathophysiology of
postgastric bypass hyperinsulinemic hypoglycemia is not
well understood. Hypoglycemia usually occurs two to three
hours after meals [12]. Patients exhibit exaggerated incretin
and insulin responses after food intake [13–15]. Alterations
in other gut hormones, including peptide YY, ghrelin,
and leptin, have also been implicated in glycemic patterns
following RYGB [14, 16–19]. Pancreatic histology from
the subset of severely aﬀected patients requiring partial
pancreatectomy has been consistent with nesidioblasto-
sis in some studies, with β-cells demonstrating increased
nuclear diameter, and increases in both large and small
islets, some of irregular shape and many clustering near
ducts [9, 10]. However, it remains uncertain whether
there is true islet hyperplasia or increased β-cell mass in
this syndrome, as control samples matched for obesity
and major weight loss are not readily available [12, 20,
21].2 Journal of Obesity
The frequency of severe hypoglycemia following RYGB
and potentially related complications requiring hospitaliza-
tion, such as confusion, syncope, seizures, and/or accidental
death, is conservatively estimated from Swedish national
data to be about 0.2%. Although these data underestimate
the risk of more mild hypoglycemia not requiring hospital
evaluation, the relative risk of these severe complications is
two- to sevenfold higher after bypass than in nonoperated
persons [22]. Furthermore, glucose variability may be high
following gastric bypass [15, 23].
In this study, we used continuous glucose monitor-
ing (CGM) technology and mixed meal tolerance testing
(MMTT) to evaluate patients who presented with clini-
cally signiﬁcant neuroglycopenia following RYGB in whom
medical management had been initiated, as compared to
patients who have no symptoms of hypoglycemia following
gastric bypass. We hypothesized that CGM would be a useful
clinical tool in this population and that glycemic variability
would be better evaluated under real-life conditions at home
than by a MMTT in clinical research testing conditions.
2.Materialsand Methods
The Internal Review Board of Joslin Diabetes Center
approved this study. All subjects provided written informed
consent.Subjectsinthesymptomatic groupwere referred for
management of postgastric bypass neuroglycopenia, deﬁned
as documented hypoglycemia associated with altered mental
status or level of consciousness, with or without seizure,
requiring assistance of others. Because of the severity of
their condition, all of the symptomatic patients had already
been counseled regarding medical nutritional therapy, with
emphasis on controlled portions of low glycemic index
carbohydrates. In addition, at the time of study, 8 of 10
subjects in the symptomatic group were on α-glucosidase
inhibitor therapy to reduce or delay dietary carbohydrate
absorption to decrease the frequency of debilitating hypo-
glycemicepisodes. One patientwas onoctreotide and oneon
diazoxide. This group is therefore referred to as the treated
symptomatic group (TX-SX). Only one patient in this group
had diabetes preoperatively; this individual was taking no
diabetes medications and was without hyperglycemia at
t h et i m eo fs t u d y .S u b j e c t sd i dn o th a v ead i a g n o s i so f
hypoglycemia prior to surgery.
The control group comprised 6 women who had
undergone laparoscopic RYGB who denied any current or
previous symptoms characteristic of hypoglycemia, even
upon careful questioning by study investigators (referred to
as asymptomatic for hypoglycemia (ASX)). These subjects
were recruited through advertisements in bariatric surgical
clinicsandlocal newspapers. Nonehadknown diabetesprior
to RYGB. All subjects were weight stable, were similar in
duration following RYGB to the TX-SX study group, and
were otherwise in good health.
2.1. Mixed Meal Tolerance Testing. Octreotide and diazoxide
were held for 24 hours prior to MMTT, and α-glucosidase
inhibitors were omitted on the morning of study. Given
that subjects in the TX-SX group had severe hypoglycemic
episodes, it was felt that a longer washout period would
not be safe. Height and weight were measured using a
wall-mounted stadiometer (Holtain Ltd., Crymych, UK)
and electronic scale (model 0501; Acme Scale Co., San
Leandro, CA). Subjects were studied following a 10–12
hour overnight fast. Fasting blood samples were obtained
before a liquid mixed meal (Ensure, 9g protein, 40g
carbohydrate, 6g fat, 240mL; Abbott Laboratories, Abbott
Park, IL) with subsequent samples collected at 10, 20, 30, 60,
and 120 minutes for measurement of glucose, insulin, and
C-peptide.
During the MMTT, glucose was measured by glucose
oxidation, fasting cholesterol and high-density lipoprotein
(HDL) by cholesterol esterase assay, triglycerides via hydrol-
ysis to glycerol, and hemoglobin A1c by HPLC (Tosoh 2.2;
Tosoh Bioscience, San Francisco, CA). Insulin and C-peptide
were measured in duplicate serum samples by radioim-
munoassay (Diagnostic Systems Laboratories, Webster, TX).
2.2.ContinuousGlucoseMonitoring. Within onemonthafter
completion of the MMTT, study participants underwent
placement of a continuous glucose monitor (Medtronic
Minimed iPro, Medtronic, Northridge, CA). A study nurse
inserted the CGM according to manufacturer directions
and provided participants with instructions regarding CGM
maintenance and capillary blood glucose monitoring every 6
hoursforCGMcalibration.ParticipantsworetheCGMforat
least 72, and up to 120, continuous hours; during that time,
they kept a log documenting capillary blood glucose results
as well as symptoms experiencedat any time.CGMdatawere
analyzed with Minimed iPro software version 2.1A.
2.3. Statistical Analysis. Data are expressed as mean ± stan-
dard error unless otherwise indicated. Calculation of sensi-
tivity and speciﬁcity for CGM and MMTT was performed
according to the following formulas: sensitivity = number of
true positives/(number of true positives + number of false
negatives); speciﬁcity = number of true negatives/(number
of true negatives + number of false positives). A true
positive was deﬁned as a numerical value of hypoglycemia
(glucose <70mg/dL) during a test in a subject with the prior
clinical occurrence of neuroglycopenia, as these patients (in
the TX-SX group) had all had multiple episodes of well-
documented hypoglycemia associated with altered mental
status requiring assistance of others. A false positive was
deﬁned as a numerical value of hypoglycemia during a test
in a subject with no history of symptomatic hypoglycemia
(ASX) and no symptoms of hypoglycemia during the test (as
self-reported on symptom log during CGM and as assessed
by a study nurse during MMTT).
Two-tailed Student’s t-test, or Mann-Whitney nonpara-
metric test if data were not normally distributed, was used
to compare the results between groups. Repeated measures
ANOVA was used to compare variables at several time points
after a mixed meal. Statistical analysis was performed using
StatView (SAS Institute, Inc., Cary, NC). Signiﬁcance was set
at P<. 05.Journal of Obesity 3
Table 1: Characteristics of study subjects.
Gastric bypass with neuroglycopenia (TX-SX)
(n = 10)
Gastric bypass asymptomatic (ASX)
(n = 6)
Age (years) 51 ±45 2 ±5
Preoperative body mass index (kg/m2)5 0 .1 ±2.54 6 .2 ±3.4
Body mass index at evaluation (kg/m2)2 9 .8 ± 1.93 0 .0 ±2.7
Magnitude of weight loss (kg) 53.0 ±8.84 5 .0 ±5.4
Postoperative duration (years) 8.9 ±2.45 .3 ±0.9
Hemoglobin A1c (%) 5.7 ±0.15 .7 ±0.1
Total cholesterol (mg/dL) 170.1 ±7.9 173.5 ±8.4
Triglycerides (mg/dL) 66.2 ±4.97 2 .5 ±5.5
LDL cholesterol (mg/dL) 98.9 ±7.29 3 .0 ±10.1
HDL cholesterol (mg/dL) 62.2 ±4.37 3 .8 ±8.8
Systolic blood pressure (mmHg) 118.1 ± 4.7 117.5 ±6.9
Diastolic blood pressure (mmHg) 67.1 ±2.16 6 .5 ±2.9
Dumping score 64.7 ±18.76 0 .5 ±25.5
Characteristicspresented as mean ± standard error. There was no statisticallysigniﬁcant diﬀerence in these variables between the two groups.
3.Resultsand Discussion
3.1. Results. Characteristics of the 16 subjects are summa-
rizedinTable1.Subjectsinthetreatedsymptomatic(TX-SX)
group, who had symptomatic neuroglycopenia after gastric
bypass, were similar to those who remained asymptomatic
(ASX) with respect to age, preoperative and current body
mass index (BMI), magnitude of weight loss and duration
of time since RYGB; the TX-SX and ASX group were also
similar with respect to hemoglobin A1c, lipid levels and
blood pressure at time of study (Table 1).
3.1.1. Mixed Meal Tolerance Test. Nine subjects in the TX-SX
group and 5 subjects in the ASX group underwent MMTT;
one subject in each group was unable to complete the
test secondary to diﬃculties obtaining intravenous access.
Fasting glucose was not diﬀerent between the TX-SX and
ASX group (73 ± 1v e r s u s7 5± 2mg/dL; P = .4). Over
the entire 2 hours, the blood glucose levels were likewise
not diﬀerent between the two groups. The area under the
curve (AUC) for glucose (0–120 minutes) (3399 ± 695
versus 2285 ±78mg/dL/min; P = .5) and repeated measures
ANOVA comparing the glucose levels over 2 hours were not
signiﬁcantlydiﬀerent(P = .2).However,at120minutesafter
meal, the ASX group had signiﬁcantly lower blood glucose
than the TX-SX group (71±1v e r s u s7 7±3mg/dL;P = .05).
Neither fasting insulin levels (3.6 ± 0.8v e r s u s3 .2 ±
0.9μU/mL; P = .7) nor insulin AUC (5478 ± 867 versus
4308±801μU/mL/min; P = .5)during MMTT was diﬀerent
between the TX-SX and ASX groups. However, consistent
with a hyperinsulinemic etiology of hypoglycemia, there
was a trend towards greater insulin secretion in the TX-
SX group including HOMA-IS (151 ± 41 versus 73 ± 20;
P = .16) [24]. Insulin levels also tended to be higher in
the TX-SX group at 30 and 60 minutes (time 30: 129 ± 27
versus 88 ± 20μU/mL, P = .30; time 60: 25 ± 5v e r s u s
15±4μU/mL,P = .15),thoughthesedidnotreachstatistical
signiﬁcance. Similarly, fasting C-peptide levels, C-peptide
AUC, and repeated measures ANOVA for all time points
during the MMTT were also not diﬀerent between the
TX-SX and ASX groups (data not shown). There was also no
diﬀerence in insulin resistance between the TX-SX and ASX
(HOMA-IR: 0.65 ± 0.13 versus ASX 0.45 ± 0.15; P = .16)
[24].
We also assessed whether dumping syndrome physiology
was contributing to symptoms during the MMTT [25].
However, we identiﬁed no diﬀerence in the average dumping
scores of the two groups (65 ± 19 versus 60 ± 25, P = .8).
3.1.2. Continuous Glucose Monitoring. All subjects wore
CGM for a minimum of 3 days. The TX-SX group tended
to wear the device for longer and as a result had a
higher number of average sensor values (interstitial glucose
readings) (1099 ± 75 versus 721 ± 5; P = .01). As a result,
all data for glycemic excursions are expressed as number of
events of, or minutes spent in, hypo- or hyperglycemia per
day (24-hour period of sensor recordings). Data are also
expressed as percent time per day within a given glycemic
range [26].
The average interstitial glucose was similar between the
two groups (TX-SX: 104 ± 3 versus ASX 101 ± 3mg/dL;
P = 1.0). The TX-SX group had more total abnormal
glucose excursions compared to the ASX group (8.5 ± 2.1
versus 3.8 ± 2.3; P = .05), that is, including both hypo-
glycemic (<70mg/dL) and hyperglycemic (>180mg/dL)
glucose excursions.
Hypoglycemia. CGM data were analyzed to determine fre-
quencyofhypoglycemia.Excursionsduringwhichinterstitial
glucose fell below 70mg/dL per day occurred twofold more
frequently in the symptomatic group, though this did not
reach statistical signiﬁcance (1.45 ± 0.42 versus 0.78 ± 0.44;
P = .1). Similar patterns were observed when expressed
as minutes per day or percent time per day spent in4 Journal of Obesity
hypoglycemia (<70mg/dL), with hypoglycemia two times
more frequent in the TX-SX group (TX-SX 63 ± 23 versus
34 ± 22min per day, P = .28; 5.5 ± 1.9v e r s u s3 .1 ± 2.0%
time per day, P = .23). Excursions <60mg/dL were also not
signiﬁcantly diﬀerent in the TX-SX and ASX groups (TX-SX
30 ± 14versus18 ± 12min perday,P = .45;2.6 ± 1.2v er s us
3.1 ± 1.6% time per day, P = .39). The average minimum
interstitial glucose values were not signiﬁcantly lower in the
TX-SX group (58 ± 5v e r s u s6 4± 7mg/dL;P = .46).
Hyperglycemia. The maximum interstitial glucose value was
signiﬁcantly higher in the TX-SX group compared to the
ASX group (213 ± 13 versus 167 ± 13mg/dL; P = .03).
Although the TX-SX group spent more minutes per day and
more percent time per day in hyperglycemia (>180mg/dL),
the diﬀerence was not statistically signiﬁcant (TX-SX 11 ± 3
versus9 ± 6minperday ,P = .59;1.0 ± 0.3versus0.6 ± 0.4%
time per day, P = .30).
3.1.3. Sensitivity and Speciﬁcity of Tests. Nine of 10 (90%)
subjects who had experienced documented neuroglycopenia
and were actively treated for post-bypass hypoglycemia
syndrome developed hypoglycemia on CGM whereas only
3 of 9 (33%) demonstrated hypoglycemia on MMTT. In
comparison, 3 of 6 asymptomatic subjects (50%) had
hypoglycemia (<70mg/dL) on CGM, and even more, 3 of
5 (60%), on MMTT. This corresponds to a sensitivity of
90% and speciﬁcity of 50% for CGM, and 33% and 40% for
MMTT (Table 2).
4.Discussion
In this study, continuous glucose monitoring technology
is compared to standardized mixed meal tolerance test-
ing in a cohort of patients with a history of postgastric
bypass neuroglycopenia and an asymptomatic postgastric
bypass group. Patients with history of neuroglycopenia were
referred for medical evaluation after initiation of therapeutic
interventions. Our data suggest that CGM may be a better
tool for the diagnosis of glycemic variability in patients
with clinically signiﬁcant post-bypass hypoglycemia than
MMTT, even in treated patients. The diagnosis of post-
gastric bypass hypoglycemia can be challenging to make, as
hypoglycemic symptoms are nonspeciﬁc and can be diﬃcult
to distinguish from dumping syndrome [23]. There are
currently no published recommendations to guide clinicians
in the evaluation of patients suspected of having this
syndrome. In our study, CGM had a sensitivity of 90%
and speciﬁcity of 50%, compared to only 33% and 40%
for MMTT, to distinguish patients with history of neuro-
glycopenia. The diﬀerence between testings may be because
MMTT captures only one meal compared to many with
CGM. Furthermore, the meal size, nutrient composition,
and concurrent activity level, which are likely diﬀerent in
real life compared to research conditions, could play a role
in the magnitude of postprandial hypoglycemia. Similarly,
diﬀerences in counterregulatory or stress hormones, such as
cortisol or catecholamines, could also attenuate postprandial
hypoglycemia in the research setting. Until the reason for
the diﬀerence in testing results can be better elucidated or
additional diagnostic options are available, CGM appears to
be a potentially valuable diagnostic test.
Measurement of interstitial glucose by CGM has previ-
ously been validated for the detection of hypoglycemia in
other patient populations [27] and comparison of CGM
to corresponding blood glucose levels demonstrated high
accuracy duringboth euglycemiaand hypoglycemia[26, 28].
A prior case report [23]f o u n dC G Mu s e f u lt od o c u m e n t
hypoglycemia and response to treatment in a single post-
bypass patientwith type 2 diabetes. Vidal et al. [15]a l s ou s e d
CGMinpost-bypasspatients,butsubjectswithsymptomatic
hypoglycemic episodes were speciﬁcally excluded. Our data
therefore extend the current literature on glycemic excur-
sions in response to gastric bypass, in particular in those
who develop the rare but well-established syndrome of post-
bypass neuroglycemia, which can result in life-threatening
adverse events.
The data presented in this paper also provide addi-
tional insight into the eﬀects of gastric bypass on glucose
homeostasis. Patients who have had neuroglycopenia after
gastric bypass experience an average of about 63 minutes
per day with an interstitial glucose below 70mg/dL and 30
minutes per day with an interstitial glucose below 60mg/dL.
Although interstitial glucose in the hypoglycemic range was
increased about twofold in theT X - S Xg r o u p ,t h e s eﬁ n d i n g s
were not statistically signiﬁcant. This may be related to
t h ef a c tt h a tm o s ts u b j e c t sh a ds u c hs e v e r eh y p o g l y c e m i c
episodes that treatment had already been initiated at the
time of study and could not safely be withheld during CGM.
It may have also been a result of small sample size, and
alternatively, or perhaps additionally, statistical signiﬁcance
maynothavebeenachievedbecauseoftheunexpectedlyhigh
ratesofhypoglycemiadetectedonCGMintheasymptomatic
group.
Indeed, even in those without symptoms of hypo-
glycemia after RYGB, low glucose levels may occur more
frequently than commonly recognized. In our series, 3
out of 6 (50%) completely asymptomatic individuals had
an interstitial glucose below 70mg/dL; 2 out of 6 (33%)
h a dav a l u eb e l o w6 0 m g / d L( a n da sl o wa s4 0 m g / d L ) .
This is consistent with our prior report that one-third
of asymptomatic patients developed hypoglycemia (plasma
glucose <60mg/dL) after MMTT, but higher than the 12.5%
ofasymptomatic patientsreported tohavehad hypoglycemia
(glucose <50mg/dl) on CGM by Vidal et al. [15]. The
diﬀerences may be related to diﬀerent threshold deﬁnitions
of hypoglycemia, small sample sizes in all studies, and
methodology used for evaluation. Given that a dispropor-
tionate increase in death rates due to accidents has been
reported after gastric bypass [7], ﬁnding signiﬁcant rates of
hypoglycemia in symptom-free post-bypass subjects raises
the question about whether such accidents might be related
to unrecognized hypoglycemia. Furthermore, why at similar
glucose concentration some patients experience symptoms
while others do not is not understood; adaptive mechanisms
to hypoglycemia or susceptibility to neuroglycopenia may
vary between individuals after gastric bypass, but these
potential diﬀerences merit further study.Journal of Obesity 5
Table 2: Results from continuous glucose monitoring and mixed meal tolerance testing on post-gastric bypass subjects with documented
episodes of neuroglycopenia on medical treatment (TX-SX) or without any symptoms of hypoglycemia (ASX).
Gastric bypass with
neuroglycopenia
(TX-SX)
Gastric bypass
asymptomatic
(ASX)
P value
CGM
Average interstitial glucose (mg/dL) 104 ± 3 101 ±3 P = 1.00
Average number of daily excursions <70 mg/dL 1.45 ±0.42 0.78 ± 0.44 P = .10
Minutes/day glucose <70 mg/dL 63 ±23 34 ± 22 P = .28
Minutes/day glucose <60 mg/dL 30 ±14 18 ± 12 P = .45
Average minimum glucose (mg/dL) 58 ±56 4 ±7 P = .46
Average maximum glucose (mg/dL) 213 ±13 167 ±13 P = .03
Minutes/day glucose >180 mg/dL 11 ±39 ± 6 P = .59
Total abnormalglucose excursions (hypoglycemic <70 mg/dL, plus
hyperglycemic >180 mg/dL) 8.5 ±2.13 .8 ± 2.3 P = .05
MMTT
Fasting blood glucose (mg/dL) 73 ±17 5 ±2 P = .40
Glucose area under curve (0–120mins) (mg/dL/min) 3399 ±695 2285 ±782 P = .50
Glucose at time 120mins (mg/dL) 71 ±17 7 ±3 P = .05
Fasting insulin (μU/mL) 3.6 ±0.83 .2 ± 0.9 P = .70
Insulin at time 30mins (μU/mL) 129 ±27 88 ± 20 P = .30
Insulin at time 60mins (μU/mL) 25 ±51 5 ±4 P = .15
Sensitivity∗
CGM 9/10 (90%)
MMTT 3/9 (33%)
Speciﬁcity∗∗
CGM 3/6 (50%)
MMTT 2/5 (40%)
Data presented as mean ± standard error. CGM: continuous glucose monitoring; MMTT: mixed meal tolerance testing.
∗Sensitivity = number of true positives/(number of true positives + number of false negatives).
∗∗Speciﬁcity=numberoftruenegatives/(numberoftruenegatives+numberoffalsepositives).Truepositiveisdeﬁnedasanumericalvalueofhypoglycemia
(glucose<70mg/dL) during a test in a subject with the prior clinical occurrence of neuroglycopenia (TX-SX group). A false positive is deﬁned as a numerical
value of hypoglycemia during a test in a subject without the presence or history of symptoms.
Our CGM data also show that patients with prior neu-
roglycopenia following gastric bypass demonstrate higher
glycemic peaks when compared with asymptomatic post-
bypass persons (maximum interstitial glucose value 212
versus 167mg/dL; P = .03). Although we cannot directly
address the causal factors potentially responsible for this
pattern, this could be consistent with a rapid increase in
plasma glucose after oral intake potentially leading to a
high insulin peak and consequent hypoglycemia, as has
previously been proposed [29]. However, our MMTT results
did not support this, as post-MMTT glycemic response was
not higher in the TX-SX than the ASX group, and prior
published data addressing this question have not been con-
sistent [13, 29]. We previously reported that glucose levels
during the 30 minutes after MMTT were lower in a group
of subjects that had experienced neuroglycopenia (but were
treatment naive) compared to post-RYGB asymptomatic
controls [13]. In contrast, Kim et al. [29] found that 30-
minute glucose values after a 75g oral glucose tolerance
test were higher in a symptomatic hypoglycemia compared
to an asymptomatic post-bypass group. While diﬀerences
in these ﬁndings may relate to diﬀerences in the type and
carbohydratecontentoftheteststimulus,itisinterestingthat
both studies did ﬁnd that time-to-peak glucose was shorter
in the symptomatic patients. More studies are clearly needed
tobettercharacterizepostprandialglucose,insulin,andother
metabolically important hormone dynamics in patients who
develop signiﬁcant hypoglycemia after bariatric surgery.
Our main study limitation is the small sample size.
However, given that neuroglycopenia after gastric bypass
is a relatively rare phenomenon, the size of the TX-SX
cohort assembled for this study is substantial. Furthermore,
previous medical management for neuroglycopenia could
attenuate glycemic variability and aﬀect conclusions.
5.Conclusions
Asymptomatic hypoglycemia is more frequent than com-
monly recognized in post-bypass patients. The clinical
importance of these events, and why at similar glucose
levels some patients experience hypoglycemic symptoms
while others do not remains incompletely understood.6 Journal of Obesity
The underlying pathophysiology of the post-bypass hypo-
glycemia syndrome, including post-prandial glucose and
hormonal dynamics, needs to be better characterized and
warrants continued investigation. For clinicians evaluating
patients for the rare but potentially life-threatening compli-
cation of neuroglycopenia after gastric bypass surgery, CGM
may be a valuable diagnostic test.
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